From 'Undruggable' to Precision Strike: The Latest Advances in KRAS G12C Inhibitors

In the history of cancer genetics, KRAS is one of the most common and stubborn oncogenes. It drives about a quarter of solid tumors, playing a key role especially in non-small cell lung cancer, colorectal cancer, and pancreatic cancer. However, because the KRAS protein has a smooth surface and lacks an obvious drug-binding pocket, the scientific community considered it an 'undruggable' target for four decades. This situation was completely rewritten in 2021 when the first KRAS G12C inhibitor was approved.

Why can G12C be targeted?

The KRAS G12C mutation replaces glycine with cysteine at amino acid position 12. This cysteine provides a unique chemical reaction site, allowing covalent inhibitors to permanently lock the KRAS protein in the 'off' state like a key, blocking downstream cell proliferation signals. About 13% of lung adenocarcinomas and 3% of colorectal cancers carry this mutation, affecting thousands of patients in Taiwan each year.

First-generation drugs proved the concept feasible, but the objective response rate was around 40%, progression-free survival was about six to seven months, and most patients eventually developed resistance. These limitations are exactly what new-generation drugs and combination strategies aim to overcome.

Second-generation inhibitors and combination strategies

Second-generation KRAS G12C inhibitors have stronger target occupancy and longer half-lives, and early data suggest response rates may increase to over 50%. More importantly, combination strategies are emerging: in colorectal cancer, inhibiting KRAS alone triggers feedback activation of EGFR signaling, so dual blockade with a KRAS inhibitor plus an anti-EGFR monoclonal antibody has become a standard research direction; in lung cancer, combination with immune checkpoint inhibitors is being validated in phase III trials.

Regarding resistance mechanisms, research has mapped multiple escape pathways, including secondary KRAS mutations, bypass activation of RTK signaling, and histological transformation. Corresponding pan-KRAS inhibitors and KRAS G12D inhibitors have also entered early clinical trials, with G12D being the most common subtype in pancreatic cancer and considered the next important battlefield.

What does this mean for patients?

For patients with KRAS mutations, genetic testing is more important than ever. Comprehensive next-generation sequencing (NGS) can not only confirm the mutation subtype but also identify co-mutations that may affect treatment efficacy (such as STK11, KEAP1). If standard treatments are less effective than expected, participating in clinical trials may be a way to access new-generation drugs—currently, trials targeting G12C, G12D, and even pan-KRAS are recruiting at multiple medical centers in Taiwan.